Epilepsy community seeks redefinition of bioequivalence from FDA
Monday, December 9, 2013 - 14:30
in Health & Medicine
For several years, epilepsy practitioners have questioned the U.S. Food and Drug Administration’s (FDA) definition of bioequivalence as it applies to narrow therapeutic index (NTI) drugs, such as those used for epilepsy. In response to these concerns, the FDA has sponsored 3 studies of antiepileptic drugs and also convened an advisory board to help determine which drugs are NTI.